The National Audit of Pulmonary Hypertension is delivered by NHS Digital and commissioned by NHS England and measures the quality of care provided to people referred to PH services in England (including patients referred from Wales) and Scotland, by answering three key questions:

• Are pulmonary hypertension services appropriate?
• Are patients receiving the right treatment in a timely manner?
• What are the outcomes for patients with pulmonary hypertension?

The audit answers these questions through the measurement of a number of professionally agreed targets reported at a national level, and covers the time period of 1st April 2016 – 31st March 2017. It’s very encouraging to see that significantly more of the standards have been met compared to the previous year, cementing the UK’s specialist centres as the envy of the world.

For the second year, the PHA UK has taken the key findings of the report and presented them in a clear, accessible way. We’ve done this so you can see, at-a-glance, how the PH service in the UK is performing.

Once again, we’re bringing you the information that’s important to you, by including the statistics you told us you wanted to know about most.

As always, we’d love to know what you think about the findings of the National Audit of Pulmonary Hypertension and how we’ve presented them. Please email us at office@phauk.org, call us on 01709 761450 or tweet us @PHA_UK.

We hope you enjoy reading this report.

Iain Armstrong
Chair of PHA UK
In 2016/17, data for the national audit was submitted by all eight specialist PH centres:
- Golden Jubilee National Hospital, Glasgow
- Hammersmith Hospital, London
- Papworth Hospital, Cambridge
- Royal Brompton Hospital, London
- Royal Free Hospital, London
- Royal Hallamshire Hospital, Sheffield
- Freeman Hospital, Newcastle
- Great Ormond Street Children’s Hospital, London

The following four findings were chosen by PH patients to be the most important to them. The percentages shown are an average across the centres who were audited and we have highlighted the differences between the findings from 2015/16 and 2016/17. We’ve also shown the professionally agreed targets that the centres are expected to meet.

How many patients, who have had at least one consultation in the last year, have had a quality of life questionnaire recorded during that time?

- **88%**
- **90%**

**PHA UK’s view...**
Our research shows that improvement in quality of life is the number one outcome patients want from their treatment so it’s vital that it’s measured in this way.

How many patients referred to a specialist centre were seen, assessed and diagnosed within six months?

- **98%**
- **95%**

**PHA UK’s view...**
It’s encouraging to see this improvement as we often hear from patients who have been on a long and difficult journey to diagnosis.

How many patients taking PH specific drugs have had at least one consultation at a specialist PH centre within the last 13 months?

- **96%**
- **95%**

**PHA UK’s view...**
Again, it’s great to see an improvement. It’s important the patients are seen regularly to ensure they are responding correctly and safely to treatment.

How many patients received a right heart catheterisation before being given drugs to treat PH?

- **91%**
- **95%**

**PHA UK’s view...**
More patients than ever are receiving this ‘gold standard’ test, which is important in making sure the diagnosis of PH is accurate – and that the right treatment is administered.

I can’t thank everyone at my specialist centre enough for extending my life and helping me to continue enjoying my retirement and family life.

Mary Jane

Since my diagnosis at my specialist centre I feel like I’ve had an angel watching over me. The care and treatment is beyond words.

Asha

See overleaf for more key findings from the National Audit of PH
The National Audit also discovered that between 1 April 2016 – 31 March 2017:

- PH centres managed 7131 patients.
- 87% of patients had a WHO functional class and six-minute walk or shuttle exercise test recorded before being given drugs to treat PH.
- 52% of patients referred to a specialist centre attended a consultation or were discharged within 30 days.
- 100% of patients receiving drug treatment for PH had an official diagnosis recorded.
- For 91% of patients, their first line drug therapy was a phosphodiesterase 5 inhibitor.

The full National Audit of Pulmonary Hypertension, including all of the findings, is available by visiting www.content.digital.nhs.uk/ph